Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The objective of this study was to determine whether these NEXT GENERATION (NGEN) HepQuant Tests, using Risk ACE as endpoint, could detect treatment effects in MAESTRO-NAFLD-1 (NCT04197479), an open label, single arm study of resmetirom, a thyroid hormone receptor- agonist being studied for the treatment of NASH (Harrison et al., Lancet 2019, 394:2012-24)
Kidney function had deteriorated sharply, with creatinine rising to 2.51 mg/dL
Connect With Us Join us @SKINSKOOL
Cancer 45 SahraouiA.WinzellM
US$ 24.44
US$ 27.48
US$ 21.02
US$ 22.32
US$ 28.49
:max_bytes(150000):strip_icc()/VWH-GettyImages-2276706586.jpg-4e49ad1f948143ed99767b89bf0289d7.jpg)
US$ 29.56
US$ 29.72
US$ 24.05
